Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BBIO
HOLDBridgeBio Pharma, Inc. · Healthcare · United States · $16.5B · Avg Vol: $345M/d
COMPANY DESCRIPTION
BridgeBio Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for genetic diseases and genetically driven cancers. Its competitive edge stems from a diversified portfolio of therapeutic candidates across various indications and a unique "hub-and-spoke" R&D model designed to efficiently advance programs. The company aims to address significant unmet medical needs through a precision medicine approach.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77.6M | 9.3M | 221.9M | 502.1M | 86.3% | 580.0M | 961.2M | — | 91.4% |
| EPS | -3.26 | -3.95 | -2.88 | -3.78 | — | -3.71 | -2.14 | 0.57 | — |
| Shares | 150.6M | 175.1M | 190.0M | 194.8M | +29.3% | 195.9M | — | — | — |
| Debt | 1.7B | 1.7B | 1.7B | 1.9B | 2.6% | 2.5B | — | — | — |
| Equity | -1.3B | -1.4B | -1.5B | -2.1B | — | — | — | — | — |
| Op CF | -419.5M | -527.7M | -520.7M | -445.9M | — | -444.0M | — | — | — |
| Inv CF | 453.1M | 54.0M | 60.8M | -24.5M | — | — | — | — | — |
| Fin CF | -13.1M | 451.5M | 748.5M | 359.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BBIO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BBIO | BridgeBio Pharma, Inc.(you) | $16.5B | 37 | HOLD |
| MDGL | Madrigal Pharmaceuticals, Inc. | $12.6B | 36 | HOLD |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.1B | 36 | HOLD |
| AXSM | Axsome Therapeutics, Inc. | $12.4B | 44 | HOLD |
| APGE | Apogee Therapeutics, Inc. | $10.2B | 41 | HOLD |
| MRNA | Moderna, Inc. | $21.5B | 27 | SELL |
| IMVT | Immunovant, Inc. | $8.1B | 39 | HOLD |
| SYRE | Spyre Therapeutics, Inc. | $8.9B | 32 | SELL |
| NUVL | Nuvalent, Inc. | $9.8B | 30 | SELL |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.9B | 30 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%